Journal of Clinical Investigation · 1996 · 149 citations · 31 references
Life SciencesEndocrinologyPharmacologyCell SignalingMetabolic RegulationSignal TransductionCyclic Nucleotide SignalingDiabetes MellitusEndocrine SignalingHormone SecretionHormone SignalingPancreatic HormonesCamp SignalingCyclic Adenosine Monophosphate PathwayCyclic Adenosine Monophosphate SignalingG-protein-coupled Receptor Signaling In SecretionGlucagon-like Peptide-1 Receptor SignalingGlucose-dependent Insulin SecretionGlucose-stimulated Insulin SecretionPancreatic Peptide Hormones
Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino acid peptide produced by K cells of the mammalian proximal small intestine and is a potent stimulant of insulin release in the presence of hyperglycemia. However, its relative physiological importance as a postprandial insulinotropic agent is unknown. Using LGIPR2 cells stably transfected with rat GIP receptor cDNA, GIP (1-42) stimulation of cyclic adenosine monophosphate (cAMP) production was inhibited in a concentration-dependent manner by GIP (7-30)-NH2. Competition binding assays using stably transfected L293 cells demonstrated an IC50 for GIP receptor binding of 7 nmol/liter for GIP (1-42) and 200 nmol/liter for GIP (7-30)-NH2, whereas glucagonlike peptide-1 (GLP-1) binding to its receptor on ++betaTC3 cells was minimally displaced by GIP (7-30)-NH2. In fasted anesthetized rats, GIP (1-42) stimulated insulin release in a concentration-dependent manner, an effect abolished by the concomitant intraperitoneal administration of GIP (7-30)-NH2 (100 nmol/ kg). In contrast, glucose-, GLP-1-, and arginine-stimulated insulin release were not affected by GIP (7-30)-NH2. In separate experiments, GIP (7-30)-NH2 (100 nmol/kg) reduced postprandial insulin release in conscious rats by 72%. It is concluded that GIP (7-30)-NH2 is a GIP-specific receptor antagonist and that GIP plays a dominant role in mediating postprandial insulin release.
31
GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN
Bernhard Kreymann, Mohammad A. Ghatei, Gareth Williams et al. · The Lancet · 1987 · 1.9K citations
Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes
Michael A. Nauck, F. Stöckmann, R. Ebert et al. · Diabetologia · 1986 · 1.3K citations · Full text
Svetlana Mojsov, Gordon C. Weir, Joel F. Habener · Journal of Clinical Investigation · 1987 · 871 citations · Full text